kabutan

KYORIN Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 30%, Oct-Dec Ordinary Profit Decreases by 55%

Wed Feb 5, 2025 3:30 pm JST Earnings

4569 KYORIN Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

KYORIN Pharmaceutical Co.,Ltd. <4569> [TSE Prime] announced its financial results after the market closed on February 5th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2025 (April to December) dropped 30.4% from the same period last year to 3.75 billion yen. The progress rate toward the full-year plan of 6.9 billion yen was 54.4%, also falling below the five-year average of 76.0%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to surge 2.6 times that of the same period last year, reaching 3.14 billion yen.

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit significantly dropped to 1.7 billion yen, a 55.3% decrease compared to the same period last year. The operating profit margin sharply declined from 10.7% in the same period last year to 4.6%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 80,707 4,702 5,336 4,377 76.4 91.6 Feb 6, 2023 J-GAAP
Apr - Dec, 2023 87,267 4,803 5,391 4,149 72.3 79.0 Feb 6, 2024 J-GAAP
Apr - Dec, 2024 89,286 3,115 3,753 2,439 42.5 54.4 Feb 5, 2025 J-GAAP
YoY +2.3% -35.1% -30.4% -41.2% -41.3%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 64,595 4,899 5,244 3,585 62.5 32 May 10, 2024 J-GAAP
Oct - Mar, 2024 Guidance 68,261 4,951 4,850 3,745 65.2 32 Nov 7, 2024 J-GAAP
YoY +5.7% +1.1% -7.5% +4.5% +4.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 113,270 5,123 5,827 4,723 82.4 52 May 11, 2023 J-GAAP
Mar, 2024 119,532 6,234 6,822 5,475 95.4 52 May 10, 2024 J-GAAP
Mar, 2025 Guidance 123,400 6,500 6,900 5,000 87.0 52 May 10, 2024 J-GAAP
YoY +3.2% +4.3% +1.1% -8.7% -8.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 32,330 3,468 3,813 2,259 39.4 10.7 Feb 6, 2024 J-GAAP
Jan - Mar, 2024 32,265 1,431 1,431 1,326 23.1 4.4 May 10, 2024 J-GAAP
Apr - Jun, 2024 28,419 1,150 1,417 885 15.4 4.0 Jul 31, 2024 J-GAAP
Jul - Sep, 2024 26,720 399 633 370 6.4 1.5 Nov 7, 2024 J-GAAP
Oct - Dec, 2024 34,147 1,566 1,703 1,184 20.6 4.6 Feb 5, 2025 J-GAAP
YoY +5.6% -54.8% -55.3% -47.6% -47.7%

Related Articles